Cagri-Reta

Cagri-Reta combines two structurally distinct metabolic peptides engineered for extended half-life and albumin binding.

Cagrilintide is a 39-amino-acid acylated analog of amylin, the pancreatic hormone co-secreted with insulin. It acts as a non-selective agonist at amylin receptors (AMYR) and the calcitonin receptor (CTR), pathways associated with satiety signaling, gastric emptying rate, and energy balance. A C20 fatty-diacid modification and a C3–C8 disulfide bridge confer stability and a prolonged duration of action.

Retatrutide (LY3437943) is a 39-amino-acid synthetic peptide built on a GIP backbone, incorporating non-coded residues (Aib2, Aib20, α-Me-Leu13) and a C20 fatty-diacid conjugation for albumin binding. It functions as a unimolecular triple agonist of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R), reported binding affinities place it in the low-nanomolar range across all three targets.

The blend brings together amylin-receptor signaling and combined incretin/glucagon-receptor signaling, two mechanistically independent axes of metabolic and energy-balance regulation, within a single formulation. Both components are supplied as lyophilized powder.

Disclaimer: This product is intended strictly for laboratory and in-vitro applications. It is not a drug, food, or cosmetic and is not for human or veterinary consumption. Not for diagnostic or therapeutic use. Handling should be performed only by qualified personnel.